TY - JOUR
T1 - Quality of reporting of serious adverse drug events to an institutional review board
T2 - A case study with the novel cancer agent, imatinib mesylate
AU - Dorr, David A.
AU - Burdon, Rachel
AU - West, Dennis P.
AU - Lagman, Jennifer
AU - Georgopoulos, Christina
AU - Belknap, Steven M.
AU - McKoy, June M.
AU - Djulbegovic, Benjamin
AU - Edwards, Beatrice J.
AU - Weitzman, Sigmund A.
AU - Boyle, Simone
AU - Tallman, Martin S.
AU - Talpaz, Moshe
AU - Sartor, Oliver
AU - Bennett, Charles L.
PY - 2009/6/1
Y1 - 2009/6/1
N2 - Purpose: Serious adverse drug event (sADE) reporting to Institutional Review Boards (IRB) is essential to ensure pharmaceutical safety. However, the quality of these reports has not been studied. Safety reports are especially important for cancer drugs that receive accelerated Food and Drug Administration approval, like imatinib, as preapproval experience with these drugs is limited. We evaluated the quality, accuracy, and completeness of sADE reports submitted to an IRB. Experimental Design: sADE reports submitted to an IRB from 14 clinical trials with imatinib were reviewed. Structured case report forms, containing detailed clinical data fields and a validated causality assessment instrument, were developed. Two forms were generated for each ADE, the first populated with data abstracted from the IRB reports, and the second populated with data from the corresponding clinical record. Completeness and causality assessments were evaluated for each of the two sources, and then compared. Accuracy (concordance between sources) was also assessed. Results: Of 115 sADEs reported for 177 cancer patients to the IRB, overall completeness of adverse event descriptions was 2.4-fold greater for structured case report forms populated with information from the clinical record versus the corresponding forms from IRB reports (95.0% versus 40.3%, P < 0.05). Information supporting causality assessments was recorded 3.5-fold more often in primary data sources versus IRB adverse event descriptions (93% versus 26%, P < 0.05). Some key clinical information was discrepant between the two sources. Conclusions: The use of structured syndrome-specific case report forms could enhance the quality of reporting to IRBs, thereby improving the safety of pharmaceuticals administered to cancer patients.
AB - Purpose: Serious adverse drug event (sADE) reporting to Institutional Review Boards (IRB) is essential to ensure pharmaceutical safety. However, the quality of these reports has not been studied. Safety reports are especially important for cancer drugs that receive accelerated Food and Drug Administration approval, like imatinib, as preapproval experience with these drugs is limited. We evaluated the quality, accuracy, and completeness of sADE reports submitted to an IRB. Experimental Design: sADE reports submitted to an IRB from 14 clinical trials with imatinib were reviewed. Structured case report forms, containing detailed clinical data fields and a validated causality assessment instrument, were developed. Two forms were generated for each ADE, the first populated with data abstracted from the IRB reports, and the second populated with data from the corresponding clinical record. Completeness and causality assessments were evaluated for each of the two sources, and then compared. Accuracy (concordance between sources) was also assessed. Results: Of 115 sADEs reported for 177 cancer patients to the IRB, overall completeness of adverse event descriptions was 2.4-fold greater for structured case report forms populated with information from the clinical record versus the corresponding forms from IRB reports (95.0% versus 40.3%, P < 0.05). Information supporting causality assessments was recorded 3.5-fold more often in primary data sources versus IRB adverse event descriptions (93% versus 26%, P < 0.05). Some key clinical information was discrepant between the two sources. Conclusions: The use of structured syndrome-specific case report forms could enhance the quality of reporting to IRBs, thereby improving the safety of pharmaceuticals administered to cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=66649132782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66649132782&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-08-1811
DO - 10.1158/1078-0432.CCR-08-1811
M3 - Article
C2 - 19458059
AN - SCOPUS:66649132782
SN - 1078-0432
VL - 15
SP - 3850
EP - 3855
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 11
ER -